Stay updated with breaking news from Vstm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Analysts expect Verastem, Inc. (NASDAQ:VSTM – Get Rating) to report ($0.10) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Verastem’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.11). Verastem also reported earnings per share of ($0.10) in the same quarter last year. […]
Verastem (NASDAQ:VSTM – Get Rating) issued its earnings results on Monday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), MarketWatch Earnings reports. Verastem had a negative net margin of 3,468.09% and a negative return on equity of 76.14%. Shares of VSTM traded up […]
Verastem (NASDAQ:VSTM – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target […]
Verastem (NASDAQ:VSTM – Get Rating)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Zacks.com reports. Cantor Fitzgerald also issued estimates for Verastem’s FY2022 earnings at ($0.37) EPS. Several other research firms have also issued reports on VSTM. Truist Financial began […]
Verastem (NASDAQ:VSTM – Get Rating) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01, MarketWatch Earnings reports. Verastem had a negative return on equity of 74.56% and a negative net margin of 3,468.09%. NASDAQ VSTM traded up $0.04 on Wednesday, […]